Lebrikizumab Shows Benefit in Pediatric Atopic Dermatitis Via Selective IL-13 Blockade
Selective IL-13 inhibition with lebrikizumab showed benefit in pediatric atopic dermatitis, per a new medical reference summary for clinicians.
Topic
Il 13
Topic
Il 13
Lebrikizumab Phase 3 Shows Symptom, Itch Gains in Pediatric AD
Phase 3 data show lebrikizumab improved atopic dermatitis symptoms and itch in children, extending IL-13 inhibition evidence into…
IL-13–Amphiregulin Axis Drives Chronic Itch in Allergic Contact Dermatitis
A JID letter published October 5, 2026 links IL-13-induced amphiregulin to TRPV3 and TSLP signaling, identifying a keratinocyte p…
Ebglyss Hit 53% Clearance in Hand and Foot Eczema vs 27% on Placebo
Eli Lilly's Ebglyss cleared or nearly cleared hand and foot eczema in 53% of patients versus 27% on placebo, per Medical Daily, f…
Lebrikizumab Sustains Itch and Lesion Improvements for Five Years in Moderate-to-Severe AD
Lebrikizumab maintains improvements in itch and lesions for up to five years in moderate-to-severe atopic dermatitis, extending t…
Zumilokibart Hits EASI-75 Endpoint in Phase 2 AD Trial
All three zumilokibart dose regimens beat placebo on EASI-75 at Week 16 in the Phase 2 APEX Part B study of moderate-to-severe at…
AbbVie Moves Zumilokibart Into Phase 3 Atopic Dermatitis Trials
AbbVie advances its IL-13-targeting biologic zumilokibart into Phase 3 atopic dermatitis trials, adding a pipeline candidate alon…